Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

VPA-985 characterized as potent, selective, orally active V2 antagonist

Nov. 13, 1998

Sepracor announces results of phase II pilot trial for (S)-oxybutynin

Nov. 13, 1998

RenaGel available this month in the U.S.

Nov. 11, 1998

Alza focuses on urology products; licenses Urispas

Nov. 4, 1998

U.S. grants first approval for GelTex's novel phosphate-binding polymer therapeutic

Nov. 3, 1998

Synthelabo team presents new agents for incontinence

Nov. 3, 1998

Basis of beneficial effects of cactus flower in BPH

Oct. 30, 1998

Milkhaus successfully completes phase II trial of BPH therapeutic

Oct. 21, 1998

Celsion ready to begin BPH treatment studies

Oct. 20, 1998

Boston Scientific to copromote Targis System for BPH

Oct. 16, 1998

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...